APTAHEM

Aptahem's development portfolio consists of aptamers , so-called synthetic (engineered) nucleic acid polymers. An aptamer consists of either single-stranded DNA or RNA (ssDNA or ssRNA). These molecules can bind specifically to already selected targets, including proteins and peptides with high affinity and specificity. Unlike antibodies, some aptamers exhibit stereoselectivity. Aptahem develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company's leading drug candidate, is an emergency medicine that is developed with the aim of stopping the organ and tissue damage that leads to the very high mortality rate for, among other things, sepsis patients.